Date: 05-Aug-2019

Asieris, Photocure enter into a license agreement for development and commercialization of Cevira

Asieris MediTech Co, a China-based biotech company specializing in the development and commercialization of new drugs for the treatment of genitourinary tumors and related diseases, and Photocure ASA (Photocure, PHO: OSE), The Bladder Cancer Company, have announced that they have entered into a License Agreement for world-wide development and commercialization of Cevira for the treatment of HPV induced cervical precancerous lesions.